Alexander Perl
MD
Professor of Medicine, Hematology-Oncology
👥Biography 个人简介
Alexander Perl leads FLT3 inhibitor development at Penn and was principal investigator of the ADMIRAL trial establishing gilteritinib for relapsed/refractory FLT3-mutated AML. He has characterized resistance mechanisms and optimal sequencing of FLT3 inhibitors. His work has defined the FLT3 inhibitor class in AML.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Alexander Perl 的研究动态
Follow Alexander Perl's research updates
留下邮箱，当我们发布与 Alexander Perl（University of Pennsylvania Abramson Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment